Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

ABSTRACT:

Background

Granulocyte colony stimulating factor (G-CSF) and erythropoietin stimulating agents (ESA) may be used to support patients during chemotherapy. We assessed whether G-CSF or ESA were associated with progression or death in patients with ovarian cancer.

Methods

Patients with ovarian cancer following surgery, were on a protocol to evaluate bevacizumab with chemotherapy. Guidelines for administering G-CSF and ESA were specified in the protocol. Overall survival (OS) was analyzed with landmark procedures and multivariate, time-dependent hazard models.

Results

Eighteen-hundred-seventy-three women were enrolled, with no differences in clinical and pathologic variables among treatment group. Performance status, hemoglobin, and white cell counts were associated with

SUBMITTER: Stehman FB 

PROVIDER: S-EPMC3496007 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature